Community cardiology specialist Dr Peter Savill discusses five key challenges for GPs in the management of atrial ...

St. Luke’s Heart Team pioneers first EVOQUE tricuspid valve replacement in the region, offering new hope for patients with ...

May 25—dbeard @dominionpost.com Vandalia Health Mon Medical Center recently achieved another first-in-state in heart care by combining two technologies to treat atrial fibrillation — AFib. Mon Health ...

Berlin: Bayer has announced initiation of a Phase I clinical trial with BAY 3670549, an investigational highly selective ...

There is significant risk for subsequent stroke in patients hospitalized for acute exacerbation of COPD with atrial fibrillation.

Bayer initiates phase I study with GIRK4 inhibitor for treatment of patients with atrial fibrillation: Berlin Thursday, May 22, 2025, 13:00 Hrs [IST] Bayer announced initiation of ...

The phase I study evaluates BAYRY's investigational GIRK4 inhibitor, BAY 3670549, for the treatment of patients with atrial ...

BAY 3670549 is an investigational highly selective G-protein-coupled inwardly rectifying potassium channel 4 (GIRK4) inhibitor with potential to help control ...

Atrial fibrillation recurrence after catheter ... as newly prescribed or increased doses of antiarrhythmic drugs, cardioversion or repeat ablation. AF recurrence occurred in 52% of the cohort ...

"It shows that PFA is associated with lower atrial fibrillation recurrence and ... eliminating the need for time-consuming post-ablation cardioversion, avoiding antiarrhythmic drugs, and offering ...

When Do Doctors Use Cardioversion for AFib? Cardioversion is a common treatment for atrial fibrillation (AFib). AFib is a condition when the upper chambers of the heart, called atria, beat in an ...